<>
A rare genetic mutation discovered in patients with severe, treatment-resistant psoriasis explains why standard therapies fail and points toward targeted treatments that achieve complete remission, according to a study published in the Journal of Experimental Medicine.
The international research consortium, coordinated by Professor Hervé Bachelez of Université Paris Cité, the Imagine Institute in Paris, and Saint-Louis Hospital, identified mutations in the ADAR1 gene among patients with early-onset plaque psoriasis who showed no response to conventional medications or advanced biotherapies. The findings establish a new monogenic model for the condition and open a path toward precision medicine for severe skin inflammation.
Genetic Root of Treatment-Resistant Psoriasis
Psoriasis affects approximately 2.4 million people, presenting as a chronic inflammatory skin disease marked by thick red plaques and white scales. While most patients manage symptoms with standard therapies, a subset of cases remains entirely refractory to treatment.
According to the research published in July 2026, researchers found that these resistant forms stem from rare mutations in the ADAR1 gene. Under normal conditions, ADAR1 functions as a crucial immune system checkpoint. It prevents the body from triggering unnecessary inflammation in response to its own messenger RNA molecules or reacting too strongly to viral RNA.
When this regulatory mechanism fails, the immune system overreacts, producing excess inflammatory proteins including interferons and cytokines. This biochemical cascade drives chronic skin inflammation, resulting in severe physical discomfort, burning sensations, and intense itching that severely disrupts daily life for affected individuals.
Targeted Therapies Reverse Refractory Symptoms
Identifying the specific inflammatory pathway enabled clinicians to test targeted interventions. Physicians administered two medications—upadacitinib, which is already used to treat psoriatic arthritis, and deucravacitinib, prescribed for psoriasis and psoriatic arthritis—to 12 patients carrying the ADAR1 mutation.
According to the study findings, treatment responses were striking, yielding complete disease remission in patients who previously experienced no therapeutic benefit from any medications. Furthermore, skin tissue analyses uncovered an unexpected biological mechanism: inflammation in these rare forms originates not only from immune cells but also from resident skin cells, particularly pigment-producing melanocytes. This discovery accounts for the pigmentation disorders observed in up to a quarter of psoriasis patients.
Future Directions for Precision Dermatology
The discovery of the ADAR1 mutation pathway establishes immediate clinical applications and long-term research directions. In the short term, investigators aim to develop genetic screening tests to rapidly identify patients carrying the mutation and prescribe targeted therapies from the outset.
Over the long term, researchers plan to investigate whether identical underlying mechanisms drive other prevalent inflammatory conditions already frequently associated with psoriasis, such as atopic dermatitis, vitiligo, psoriatic arthritis, rheumatoid arthritis, and type 1 diabetes.
>